Naurex Inc. Company Profile, Contacts & Intelligence

Naurex Inc. Overview

Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system. Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who are unable to achieve an adequate response to their current anti-depressants. Rapastinel has shown rapid, substantial, and sustained antidepressant activity in Phase 2 clinical studies and has been well-tolerated, with none of the psychosis-like side effects that limit other drugs targeting NMDA receptors. Our second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder. In July 2015, Naurex Inc. entered into a definitive agreement to be acquired by Allergan plc. The transaction was successfully closed in August 2015. For more information, please visit www.naurex.com or www.allergan.com.

Headquarters

Administrator Jobs

Industry

Biotechnology

Naurex Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Naurex Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Naurex Inc. Workforce Composition

Seniority breakdown across 3 visible profiles.

Compare Similar Companies to Naurex Inc.

Explore companies in related markets and compare their industry and employee estimates.